NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 202)
Posted On: 06/29/2018 5:45:08 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Closes Oversubscribed Private Placement
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the closing of its oversubscribed non-brokered private placement financing, which was previously detailed on April 9, 2018. Per the update, a total of 130,779,750 units were issued under the financing at a price of $0.05 per unit for total gross proceeds of more than $6.5 million. “I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programs and management team,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “In keeping with our vision of becoming a global preventive health care company, PreveCeutical is continuing to meet key milestones with our portfolio of research and development programs that will boost shareholder value.” The company intends to use net proceeds from the financing to fund its research and development programs, as well as for general working capital purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the closing of its oversubscribed non-brokered private placement financing, which was previously detailed on April 9, 2018. Per the update, a total of 130,779,750 units were issued under the financing at a price of $0.05 per unit for total gross proceeds of more than $6.5 million. “I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programs and management team,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “In keeping with our vision of becoming a global preventive health care company, PreveCeutical is continuing to meet key milestones with our portfolio of research and development programs that will boost shareholder value.” The company intends to use net proceeds from the financing to fund its research and development programs, as well as for general working capital purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼